AGXT

Across TCGA pan-cancer cohorts, AGXT Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGXT data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AGXT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AGXT expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, STAD, and COAD are the cancer types where AGXT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.063	0.688	<.001	36	view →
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
COAD	OS	Median	All	0.159	0.799	.002	18	view →
LIHC	DFS	Median	II,III,IV	0.045	0.414	<.001	12	view →
SKCM	DFS	Median	All	0.733	0.198	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGXT–BLCA (OS)

Open the BLCA breakdown →